公开(公告)号：US09107258B1

公开(公告)日：2015-08-11

申请号：US13178336

申请日：2011-07-07

申请人： Thomas Chao ,  John Huang

发明人： Thomas Chao ,  John Huang

IPC分类号： H05B37/02 ,  H05B33/08

CPC分类号： H05B33/0815 ,  H05B33/083 ,  Y02B20/341

摘要： Methods and circuits for controlling LEDs are disclosed. In one embodiment, the light emitting diode (LED) integrated circuit controller includes a voltage regulator circuit configured to operate with an alternating current (AC) power source, where the voltage regulator circuit includes a depletion device configured to receive a varying AC voltage and to generate a unregulated voltage, and a band gap voltage reference circuit configured to received the unregulated voltage and to generate a substantially constant direct current (DC) voltage. The LED integrated circuit controller further includes a current setting circuit configured to receive the substantially constant DC voltage and to provide a substantially constant direct current to drive a series of light emitting diodes, and a second depletion device configured to protect the LED integrated circuit controller from external high voltages.

摘要翻译： 公开了用于控制LED的方法和电路。 在一个实施例中，发光二极管（LED）集成电路控制器包括配置成与交流（AC）电源一起工作的电压调节器电路，其中电压调节器电路包括被配置为接收变化的AC电压的耗尽装置， 产生未调节的电压，以及带隙电压参考电路，被配置为接收未调节的电压并产生基本恒定的直流（DC）电压。 LED集成电路控制器还包括电流设置电路，其被配置为接收基本上恒定的DC电压并提供基本上恒定的直流电流以驱动一系列发光二极管;以及第二耗尽器件，被配置为保护LED集成电路控制器 外部高电压。

公开(公告)号：US20060089855A1

公开(公告)日：2006-04-27

申请号：US10783792

申请日：2004-02-20

申请人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  John Huang

发明人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  John Huang

IPC分类号： G06Q10/00

CPC分类号： G06Q50/22 ,  G06F19/326 ,  G06F19/3456 ,  G06Q10/10 ,  G16H10/60 ,  G16H40/63 ,  G16H50/20

摘要： A medication management system (MMS) includes a medication management unit (MMU) associated with a medical device. The MMU downloads a medication order to the medical device only if information from a first input matches information from a second input. The medical device receives delivery information only from the MMU. The medication order is performed only after delivery data validation. The MMU also determines drug-drug incompatibility. The MMU can modulate (start, stop, and dynamically adjust) medication order performance. The medical device wirelessly receives a patient ID to automatically associate with the patient. During delivery, the medical device caches an updated drug library to replace an existing one. The medical device displays a patient picture for validation. The MMU evaluates the performance of medical devices and caregivers based medical device feedback. The MMU adjusts the output of medical device information conveyed to a caregiver.

公开(公告)号：US06552889B1

公开(公告)日：2003-04-22

申请号：US09908178

申请日：2001-07-17

申请人： John Huang ,  Hamza Yilmaz ,  Mohamed N. Darwish ,  Wharton McDaniel ,  Kyle Terrill ,  Peter Tu Dang

发明人： John Huang ,  Hamza Yilmaz ,  Mohamed N. Darwish ,  Wharton McDaniel ,  Kyle Terrill ,  Peter Tu Dang

IPC分类号： H02H300

CPC分类号： H03K17/0822

摘要： A power FET and a replica FET on a semiconductor chip coupled to a logic control circuit on a second semiconductor chip within a single housing. A power FET and a scaled down replica of the power FET are disposed on a semiconductor chip. The power FET is used as a switch to couple a DC power source to a load. A fraction of the power FET drain current passes through the replica FET and an external resistance. When the voltage across the external resistance exceeds a maximum value based upon the maximum allowable power FET drain current, the logic control circuit enters into a pulsed gate (PG) mode of operation. The first step in the PG mode is to switch both FETs into a non-conducting state for a predefined period of time. After this time period, a ramp voltage applied between gate and source of both FETs will switch them back into a current conducting state while holding the power FET drain current below its upper limit in the presence of a high capacitance load. If the voltage across the external resistance increases above the maximum, the PG mode of operation continues. PG mode of operation ceases and normal operation follows when the external resistance voltage remains below the established maximum. The combination of predefined nonconducting time and maximum drain current ensures operation of the power FET below maximum power dissipation limits. The PG mode of operation eliminates the need for additional temperature and thermal control circuits.

摘要翻译： 半导体芯片上的功率FET和复制FET耦合到单个壳体内的第二半导体芯片上的逻辑控制电路。 功率FET的功率FET和缩小的复制品设置在半导体芯片上。 功率FET用作将直流电源耦合到负载的开关。 功率FET漏极电流的一部分通过复制FET和外部电阻。 当外部电阻两端的电压超过最大容许功率FET漏极电流的最大值时，逻辑控制电路进入脉冲门（PG）工作模式。 PG模式的第一步是将两个FET切换到非导通状态一段预定的时间。 在这个时间段之后，施加在两个FET的栅极和源极之间的斜坡电压将在高电容负载存在的同时将功率FET漏极电流保持在其上限以下，将其切换回导通状态。 如果外部电阻两端的电压增加到最大值以上，则PG模式继续。 当外部电阻保持低于建立的最大值时，PG模式停止，正常操作。 预定义的非导通时间和最大漏极电流的组合确保功率FET的功耗低于最大功耗限制。 PG操作模式无需额外的温度和热控制电路。

公开(公告)号：US09110891B2

公开(公告)日：2015-08-18

申请号：US13316689

申请日：2011-12-12

申请人： Trausti Kristjansson ,  John Huang ,  Yu-Kuan Lin ,  Hung-ying Tyan ,  Jakob David Uszkoreit ,  Joshua James Estelle ,  Chung-yi Wang ,  Kirill Buryak ,  Yusuke Konishi

发明人： Trausti Kristjansson ,  John Huang ,  Yu-Kuan Lin ,  Hung-ying Tyan ,  Jakob David Uszkoreit ,  Joshua James Estelle ,  Chung-yi Wang ,  Kirill Buryak ,  Yusuke Konishi

IPC分类号： G06F17/28 ,  G10L15/26

CPC分类号： G06F17/289 ,  G10L13/00 ,  G10L15/26 ,  H04M3/56 ,  H04M3/568 ,  H04M2203/2061 ,  H04M2242/12 ,  H04N7/15 ,  H04N7/152

摘要： The disclosed subject matter provides a system, computer readable storage medium, and a method providing an audio and textual transcript of a communication. A conferencing services may receive audio or audio visual signals from a plurality of different devices that receive voice communications from participants in a communication, such as a chat or teleconference. The audio signals representing voice (speech) communications input into respective different devices by the participants. A translation services server may receive over a separate communication channel the audio signals for translation into a second language. As managed by the translation services server, the audio signals may be converted into textual data. The textual data may be translated into text of different languages based the language preferences of the end user devices in the teleconference. The translated text may be further translated into audio signals.

摘要翻译： 所公开的主题提供了系统，计算机可读存储介质和提供通信的音频和文本记录的方法。 会议服务可以接收来自诸如聊天或电话会议之类的通信中的参与者接收语音通信的多个不同设备的音频或视频信号。 表示由参与者输入到各个不同设备中的语音（语音）通信的音频信号。 翻译服务服务器可以通过单独的通信信道接收用于翻译成第二语言的音频信号。 由翻译服务服务器管理，音频信号可以转换为文本数据。 基于电话会议中终端用户设备的语言偏好，文本数据可以被翻译成不同语言的文本。 翻译的文本可以进一步转换成音频信号。

公开(公告)号：US20100261646A1

公开(公告)日：2010-10-14

申请号：US12664792

申请日：2008-06-18

申请人： Erin Lavik ,  Young H. Kwon ,  Markus Kuehn ,  Sandeep Saluja ,  James Bertram ,  John Huang

发明人： Erin Lavik ,  Young H. Kwon ,  Markus Kuehn ,  Sandeep Saluja ,  James Bertram ,  John Huang

IPC分类号： A61K38/18 ,  A61K31/704 ,  A61K31/7036 ,  A61K31/57 ,  A61K31/573 ,  A61K31/5365 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/505 ,  A61K31/4709 ,  A61K31/47 ,  A61K31/222 ,  A61K31/138

CPC分类号： A61K9/1647 ,  A61K9/0048 ,  A61K9/5153

摘要： Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (TOP) in the eye. In one embodiment, the microspheres are formed from polylactide-co-glycolide (“PLGA”); in another embodiment, the microspheres are formed from a blend PLGA and poly lactic acid (“PLA”). Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time. The combination of drug loading and release rate, as well as the minimization of initial burst release, result in prolonged release of a higher amount of drug.

摘要翻译： 描述了包含一种或多种活性剂，特别是可用于治疗或预防或一种或多种眼睛疾病或障碍的活性剂的生物可降解聚合物微粒组合物及其制备和使用方法。 微球组合物在体内释放有效量的一种或多种活性剂大于14天，体内优选大于60天，更优选体内至多73天，更优选在体内释放大于90天， 甚至更优选在体内超过100天，最优选在体内大于107天。 在优选的实施方案中，微粒组合物含有一种或多种用于管理眼中升高的眼内压（TOP）的活性剂。 在一个实施方案中，微球由聚丙交酯 - 共 - 乙交酯（“PLGA”）形成; 在另一个实施方案中，微球由共混PLGA和聚乳酸（“PLA”）形成。 相对亲水的，优选羧化的聚合物材料如PLGA用于药物，例如相对水溶性的马来酸噻吗洛尔，以增加药物负荷。 使用较高分子量的聚合物，以及LA（其具有较长的降解时间，长达一至两年）与GA（其具有短的降解时间，短至几天至一周）的比率被使用 提供更长时间的释放。 药物负载和释放速率的组合以及初始爆发释放的最小化导致更长量的药物释放。

公开(公告)号：US20080286315A1

公开(公告)日：2008-11-20

申请号：US12022854

申请日：2008-01-30

申请人： John Huang ,  Ding Chang ,  Shi-lung Lo ,  Feng Ping Shan

发明人： John Huang ,  Ding Chang ,  Shi-lung Lo ,  Feng Ping Shan

IPC分类号： A61K39/00 ,  A61K35/12 ,  A61P37/00 ,  C12N5/06

CPC分类号： C12N5/0639 ,  A61K38/33 ,  A61K39/0011 ,  A61K2039/5154 ,  A61K2039/55516 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/85 ,  A61K2300/00

摘要： The present invention provides a method of stimulating dendritic cells, comprising contacting the dendritic cells with methionine enkephalin. The present invention also provides methods of enhancing an immune response to an antigen in a mammal. In a first method, dendritic cells are isolated from the mammal. The dendritic cells are then contacted with methionine enkephalin for a time sufficient to stimulate the cells. Next, the stimulated dendritic cells are contacted with the antigen of interest for a time sufficient for the cells to process the antigen. The dendritic cells are then injected into the mammal. The dendritic cells may be injected into the animal either on their own, or along with methionine enkephalin and/or the antigen. In a second method, the antigen of interest and methionine enkephalin are administered to the mammal. The present invention also provides compositions for administration to a mammalian subject having a tumor.

摘要翻译： 本发明提供了一种刺激树突状细胞的方法，包括使树状细胞与甲硫氨酸脑啡肽接触。 本发明还提供增强对哺乳动物中的抗原的免疫应答的方法。 在第一种方法中，从哺乳动物中分离树突状细胞。 然后将树突状细胞与甲硫氨酸脑啡肽接触足以刺激细胞的时间。 接下来，刺激的树突状细胞与感兴趣的抗原接触足以使细胞处理抗原的时间。 然后将树突状细胞注射到哺乳动物中。 树突细胞可以自己注射入动物，或与甲硫氨酸脑啡肽和/或抗原一起注射到动物体内。 在第二种方法中，向哺乳动物施用目的抗原和甲硫氨酸脑啡肽。 本发明还提供了用于给予具有肿瘤的哺乳动物受试者的组合物。

公开(公告)号：US20060265186A1

公开(公告)日：2006-11-23

申请号：US10783642

申请日：2004-02-20

申请人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  John Huang ,  Marwan Fathallah ,  Martin McNeela

发明人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  John Huang ,  Marwan Fathallah ,  Martin McNeela

IPC分类号： G06F11/30 ,  G21C17/00

CPC分类号： G06F19/3468 ,  G06F19/00

摘要： A medication management system (MMS) includes a medication management unit (MMU) associated with a medical device. The MMU downloads a medication order to the medical device only if information from a first input matches information from a second input. The medical device receives delivery information only from the MMU. The medication order is performed only after delivery data validation. The MMU also determines drug-drug incompatibility. The MMU can modulate (start, stop, and dynamically adjust) medication order performance. The medical device wirelessly receives a patient ID to automatically associate with the patient. During delivery, the medical device caches an updated drug library to replace an existing one. The medical device displays a patient picture for validation. The MMU evaluates the performance of medical devices and caregivers based medical device feedback. The MMU adjusts the output of medical device information conveyed to a caregiver.

公开(公告)号：US20060100907A1

公开(公告)日：2006-05-11

申请号：US10783641

申请日：2004-02-20

申请人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  Raymond Silkaitis ,  John Huang ,  Bernardino Rubalcaba ,  Martin McNeela

发明人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  Raymond Silkaitis ,  John Huang ,  Bernardino Rubalcaba ,  Martin McNeela

IPC分类号： G06F19/00

CPC分类号： G06Q50/24

摘要： A medication management system (MMS) includes a medication management unit (MMU) associated with a medical device. The MMU downloads a medication order to the medical device only if information from a first input matches information from a second input. The medical device receives delivery information only from the MMU. The medication order is performed only after delivery data validation. The MMU also determines drug-drug incompatibility. The MMU can modulate (start, stop, and dynamically adjust) medication order performance. The medical device wirelessly receives a patient ID to automatically associate with the patient. During delivery, the medical device caches an updated drug library to replace an existing one. The medical device displays a patient picture for validation. The MMU evaluates the performance of medical devices and caregivers based medical device feedback. The MMU adjusts the output of medical device information conveyed to a caregiver.

公开(公告)号：US20050144043A1

公开(公告)日：2005-06-30

申请号：US10930358

申请日：2004-08-31

申请人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  Raymond Silkaitis ,  John Huang ,  Bernardino Rubalcaba ,  Martin McNeela ,  Imtiyaz Haque

发明人： Geoffrey Holland ,  Patrick Keely ,  Jeff Pelletier ,  Charles Moran ,  Raymond Silkaitis ,  John Huang ,  Bernardino Rubalcaba ,  Martin McNeela ,  Imtiyaz Haque

IPC分类号： G06F17/60

CPC分类号： G06F19/3468 ,  G06F19/00 ,  G06F19/325 ,  G06F19/326 ,  G06Q50/22 ,  G06Q50/24

摘要： A medication management system (MMS) includes a medication management unit (MMU) associated with a medical device. The MMU downloads medication delivery code based on a medication delivery order to the medical device only if information from a first input matches information from a second input. The medical device receives delivery information electronically only from the MMU. The medication order is performed only after delivery data validation. The MMU also determines drug-drug incompatibility. The MMU can modulate (start, stop, sequence and dynamically adjust) medication order performance.

摘要翻译： 药物管理系统（MMS）包括与医疗装置相关联的药物管理单元（MMU）。 只有当来自第一输入的信息匹配来自第二输入的信息时，MMU才将药物输送代码基于药物输送顺序下载到医疗装置。 医疗设备只能从MMU接收电子信息。 药物订单仅在交货数据验证后执行。 MMU还确定药物 - 药物不相容性。 MMU可以调整（启动，停止，顺序和动态调整）药物订单性能。

公开(公告)号：US6081234A

公开(公告)日：2000-06-27

申请号：US891631

申请日：1997-07-11

申请人： John Huang ,  Ronald J. Pogorzelski

发明人： John Huang ,  Ronald J. Pogorzelski

IPC分类号： H01Q3/14 ,  H01Q3/46 ,  H01Q19/06

CPC分类号： H01Q3/14 ,  H01Q19/06 ,  H01Q3/46

摘要： A novel means of scanning a circularly polarized reflectarray antenna. The reflectarray is an array of metallic elements arranged on a surface designed to compensate for the various path lengths of the optical rays from an illuminating feed to the reflecting surface and then to the antenna aperture. With appropriate design, the phase in the aperture can be made to vary linearly in any desired direction and also to produce a radiated beam normal to the constant phase surface. In the case of circular polarization, this path length compensation can be accomplished by rotation of the individual elements.

摘要翻译： 扫描圆偏振反射阵列天线的新颖手段。 反射阵列是布置在表面上的金属元件阵列，设计成用于补偿从照明馈送到反射表面然后到天线孔径的光线的各种路径长度。 通过适当的设计，可以使孔径中的相位在任何所需方向上线性变化，并且还产生垂直于恒定相面的辐射光束。 在圆极化的情况下，可以通过各个元件的旋转来实现该路径长度补偿。